Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 20/20 | 0.81 |
| ▸ | ACE | P12821 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969887 | 0.92 | MME (0.88) | MMEACE | |
| SCHEMBL11969881 | 0.92 | MME (0.88) | MMEACE | |
| SCHEMBL11969885 | 0.92 | MME (0.88) | MMEACE | |
| SCHEMBL11969690 | 0.90 | MME (1.00) | MMEACE | |
| SCHEMBL11969537 | 0.88 | MME (0.64) | MME | |
| SCHEMBL11969540 | 0.88 | MME (0.64) | MME | |
| SCHEMBL11969902 | 0.85 | MME (0.75) | MMEACE | |
| SCHEMBL19885527 | 0.85 | MME (0.75) | MMEACE | |
| SCHEMBL11970038 | 0.84 | MME (0.69) | MMEACE | |
| SCHEMBL12480836 | 0.84 | MME (0.69) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130642-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9724359-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334245-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2675795-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20140364603-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853427-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8481044-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130642-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20140364603-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.